Baxter International Inc. (BAX)
Baxter International: The Vantive Transition Complicates Margin Recovery
Baxter International is rated Hold, with a $25 target price and limited 2.6% upside, reflecting muted near-term margin recovery. Revenue growth is supported by Advanced Surgery and compounding, but infusion solutions face structural headwinds, and Novum IQ LVP supply issues persist. Margins lag revenue growth; cost reductions and inventory normalization may help, but transition expenses and debt reduction remain priorities through 2027.
Are Investors Undervaluing Baxter International (BAX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Baxter International (BAX) Stock Outpacing Its Medical Peers This Year?
Here is how Baxter International (BAX) and Bayer Aktiengesellschaft (BAYRY) have performed compared to their sector so far this year.
BAX Raises 2026 Outlook as Strong Q2 Growth Offsets Margin Pressure
Baxter raises its 2026 sales and earnings outlook after strong Q2 growth, though manufacturing costs, tariffs and pricing pressure margins.
Baxter International: The Gains Can Continue, But Should Slow
Baxter International has shown early signs of a turnaround, with improving execution and raised revenue guidance supporting cautious optimism. BAX's valuation has expanded from distressed levels, now trading at ~13x earnings and ~9.5x EV/EBITDA, yet remains attractive if growth continues. Management's focus on operational improvements, cost savings, and a conservative outlook suggests potential for further upside if EPS growth materializes.
BAX Stock Gains on Q2 Earnings & Sales Beat, Margins Contract
Baxter beats second-quarter earnings and revenue estimates, posts broad-based segment growth and raises its 2026 outlook despite margin pressure.
Baxter International Inc. (BAX) Q2 2026 Earnings Call Transcript
Baxter International Inc. (BAX) Q2 2026 Earnings Call Transcript
Baxter (BAX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Baxter (BAX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Baxter International (BAX) Surpasses Q2 Earnings and Revenue Estimates
Baxter International (BAX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.59 per share a year ago.
Watch These 4 Medical Product Stocks for Q2 Earnings: Beat or Miss?
Medical product makers face Q2 margin pressure from tariffs and inflation even as demand stays strong. See which earnings reports could surprise.
Will Baxter's Q2 Results Continue to Reflect Operational Headwinds?
BAX's second-quarter results may reflect pressured earnings and sales as manufacturing inefficiencies, inflation, and product holds offset steady demand across segments.
Earnings Preview: Baxter International (BAX) Q2 Earnings Expected to Decline
Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
